



## Medical Coverage Policy

Effective Date .....10/15/2025

Next Review Date .....2/15/2026

Coverage Policy Number..... 0500

# Pharmacogenetic Testing

## Table of Contents

|                                        |    |
|----------------------------------------|----|
| Overview .....                         | 2  |
| Coverage Policy .....                  | 2  |
| Coding Information .....               | 2  |
| General Background .....               | 5  |
| Health Equity Considerations.....      | 9  |
| Medicare Coverage Determinations ..... | 9  |
| References.....                        | 9  |
| Revision Details .....                 | 20 |

## Related Coverage Resources

[Genetics](#)  
[Inflammatory Bowel Disease - Testing for the Diagnosis and Management](#)  
[Laboratory Management Guidelines](#)  
[Laboratory Testing Services](#)  
[Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications](#)

## INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy

*will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.*

## Overview

This Coverage Policy addresses pharmacogenetic testing. Pharmacogenetics is the study of gene variations within an individual's deoxyribonucleic acid (DNA) and how these differences influence an individual's response to medications.

For additional information regarding pharmacogenetic testing for oncologic, hematologic, and other conditions, please see the Laboratory Management Guidelines and Cigna Coverage Policy "Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications" in the Related Coverage Resources section above.

## Coverage Policy

**Coverage for genetic testing varies across plans. Refer to the customer's benefit plan document for coverage details.**

**Pharmacogenetic testing (e.g., genotyping, pathogenic/likely pathogenic variant analysis) is considered medically necessary when ALL of the following criteria are met:**

- The individual is a candidate for a targeted drug therapy associated with a specific gene biomarker or gene pathogenic/likely pathogenic variant.
- The results of the pharmacogenetic test will directly impact clinical decision-making.
- The testing method is considered to be scientifically valid to identify the specific gene biomarker or gene pathogenic/likely pathogenic variant.
- **EITHER** of the following:
  - Identification of the specific gene or biomarker for use with a specific drug target has been demonstrated to improve clinical outcomes for the individual's condition being addressed.
  - Identification of the gene biomarker is noted to be clinically necessary prior to initiating therapy with drug target as noted within the U.S. Food and Drug Administration (FDA)-approved prescribing label.

**Pharmacogenetic screening in the general population is considered not medically necessary.**

**Gene expression classifiers for pharmacologic response are not covered or reimbursable.**

## Coding Information

### Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare and Medicaid Services (CMS) code updates may occur more frequently than policy updates

- Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

| <b>CPT®* Codes</b> | <b>Description</b>                                                                                                                                                                                                     |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81247              | G6PD (glucose-6-phosphate dehydrogenase) (eg, hemolytic anemia, jaundice), gene analysis; common variant(s) (eg, A, A-)                                                                                                |
| 81400              | Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis)                                             |
| 81401              | Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat) |
| 81405              | Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)        |

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

| <b>CPT®* Codes</b> | <b>Description</b>                                                                                                                        |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| 81227              | CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *5, *6) |

| <b>ICD-10 CM Codes</b> | <b>Description</b> |
|------------------------|--------------------|
| G35.A-G35.D            | Multiple sclerosis |

**Not Covered or Reimbursable:**

| <b>ICD-10-CM Diagnosis Codes</b> | <b>Description</b>        |
|----------------------------------|---------------------------|
|                                  | All other diagnosis codes |

**Not Covered or Reimbursable:**

| <b>CPT®* Codes</b> | <b>Description</b>                                                                                                                               |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| 81225              | CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17) |
| 81230              | CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism), gene analysis, common variant(s) (eg, *2, *22)                     |
| 81231              | CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)        |
| 81283              | IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant                                                              |

| <b>CPT®* Codes</b> | <b>Description</b>                                                                                                                                                                                                                                         |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 81328              | SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)                                                                                                               |
| 81355              | VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T)                                                                                                          |
| 81418              | Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis                                                                      |
| 0029U              | Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823)                                                                       |
| 0030U              | Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823)                                                                                                                                              |
| 0031U              | CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)                                                                                                                        |
| 0032U              | COMT (catechol-O-methyltransferase) (eg, drug metabolism) gene analysis, c.472G>A (rs4680) variant                                                                                                                                                         |
| 0033U              | HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G])               |
| 0173U              | Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes                                                                                                                                                        |
| 0175U              | Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes                                                                                                                                                                 |
| 0345U              | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6                                                             |
| 0347U              | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes                                                                                           |
| 0348U              | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes                                                                                           |
| 0349U              | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions                                                |
| 0350U              | Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes                                                                                           |
| 0380U              | Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype                                                                  |
| 0392U              | Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug |
| 0411U              | Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6                                                             |

| <b>CPT®*<br/>Codes</b> | <b>Description</b>                                                                                                                                                                                                                                                                                                                                                         |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 0419U                  | Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype                                                                                                                                                                                                             |
| 0423U                  | Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition                                                                                                                                                                              |
| 0434U                  | Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes                                                                                                                                                                                                                                  |
| 0437U                  | Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score                                                                                                                                                                                                               |
| 0438U                  | Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions                                                                                                                    |
| 0456U                  | Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anticyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy |
| 0460U                  | Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes                                                                                                                                                                                                           |
| 0461U                  | Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes                                                                                                                                   |
| 0476U                  | Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes (Code effective 10/01/2024)                                                    |
| 0477U                  | Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes (Code effective 10/01/2024)         |
| 0516U                  | Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status (Code effective 10/01/2024)                                                                                                                                                                                                   |

| <b>HCPCS<br/>Codes</b> | <b>Description</b>                                                                               |
|------------------------|--------------------------------------------------------------------------------------------------|
| G9143                  | Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) |

**\*Current Procedural Terminology (CPT®) ©2024 American Medical Association: Chicago, IL.**

## General Background

Pharmacogenetics, or pharmacogenomics, is the study of gene variations within an individual's deoxyribonucleic acid (DNA) and how these differences influence an individual's response to medications. An individual's unique genetic makeup helps determine how he or she responds to a drug and whether or not side effects or adverse reactions may be experienced. Variations in genes may also cause an individual to metabolize a drug more quickly, more slowly or at the same rate as anticipated, based on dosage. Pharmacogenetics encompasses variations in genes that encode drug transporters, drug-metabolizing enzymes and drug targets, as well as specific genes related to the action of drugs. A slight variation DNA can result in a subtle change in a protein which translates into major differences in how the protein functions. A pharmacogenetic test is meant to guide treatment strategies, patient evaluations and decisions based on its ability to predict response to treatment in particular clinical contexts.

A particular variant is not always phenotype-specific in that it may have a different impact depending on the drug in question. Racial and ethnic differences in the frequency and nature of genetic variants are also possible and should be recognized in translating outcomes from one population to another. The relation of a gene or gene biomarker and a drug target must be validated for each therapeutic indication in different racial and ethnic groups, as well as in different treatment and disease contexts (Crews, et al., 2012).

Although genetics has an impact on genes related to inter-individual differences in drug response, it is only one of the many variables affecting these genes. Other factors include the characteristics of the condition for which the drug is prescribed, co-administration of other drugs, and non-genetic factors, including the individual's diet, weight, and smoking habits. Identification of gene variations may be clinically useful in a small number of drugs; however, it may be insufficient in others to explain complex differences in metabolism, efficacy and toxicity. The presence of polymorphisms alone may be a poor predictor of phenotype because of variability.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; however, laboratories offering such tests as a clinical service must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA) and must be licensed by CLIA for high-complexity testing. Additionally, laboratories in the U.S. should follow the College of American Pathologists (CAP) guidelines. High complexity techniques used for pharmacogenetic testing include immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR) and microarray assays. According to the U.S. Food and Drug Administration (FDA) (2007), diagnostic tests that assay the presence of a particular pattern (e.g., single nucleotide polymorphism [SNP] set, haplotype pattern) should ideally be validated in a prospective clinical trial.

An increasing number of multigene genotyping panels with the goals of detecting inter-individual differences in drug metabolism and response to a variety of drug targets are commercially available. The number of gene biomarkers and gene mutations and associated drug targets which are tested for vary widely between tests; some tests evaluate for a few biomarkers and associated drug targets while others may include hundreds of biomarkers within the test. Some multigene assays assess for the presence or absence of multiple biomarkers and provide lists of potential therapeutic agents, clinical trials and review of published literature associated with the biomarkers that are identified in the patient sample.

### **Clinical Utility**

The clinical use of a genetic test should be based on analytical validity (i.e., analytical sensitivity and specificity), and clinical validity (i.e., clinical sensitivity and specificity), and both positive and negative predictive value. Before a genetic test can be generally accepted in clinical practice, data

must be collected to demonstrate the benefits and risks from both positive and negative results (i.e., the test must have clinical utility).

The clinical usefulness or utility of pharmacogenetic testing is the extent to which results of testing will impact clinical decision-making and improve health outcomes. Pharmacogenetic test results are meant to guide patient evaluation and treatment strategy and decisions based on the ability to predict response to treatment in particular clinical contexts, and to allow the clinician to predict an individual's response to specific pharmacotherapy, assist in making treatment choices, individualize drug dosages in order to maintain a consistent drug level in the body and avoid adverse reactions from overdose or suboptimal effects from under medication (Cicali, et al., 2025). The integration of genomic data in patient treatment requires evidence of consistency and size of measured effects, medication compliance and phenoconversion. The effects of ethnicity must be evaluated, especially in the context of global drug development and extrapolation of clinical trial genomic data from one population to another (Ehmann, et al., 2014).

When applied in a clinical setting, the information from these tests can potentially identify individual variability in drug response, including both effectiveness and toxicity. The individual for whom testing is proposed should be a candidate for a targeted drug therapy associated with a specific gene biomarker or gene mutation and the results of testing must directly impact clinical decision making. The identification of the specific gene or biomarker for use with a specific drug target must also be demonstrated by published, peer-reviewed clinical trial data to improve clinical outcomes for an individual receiving that specific treatment and be considered scientifically valid to identify the biomarker.

### **Gene Expression Classifiers**

The genetic basis for disease is determined by the inheritance of genes containing specific sequences of DNA. The phenotypic expression of these genes, through the synthesis of specific proteins, involves interaction with environmental signals that trigger activation of particular genes. Ribonucleic acid (RNA) is transcribed from a DNA template; messenger RNA (mRNA) is then translated into protein. Transcription and translation underlie gene expression. Three to five percent of genes are active in a particular cell, even though all cells have the same information contained in their DNA. Most of the genome is selectively repressed, a property that is governed by the regulation of gene expression, mostly at the level of transcription (i.e., the production of messenger RNA from the DNA). In response to a cellular perturbation, changes in gene expression take place that result in the expression of hundreds of gene products and the suppression of others. This molecular heterogeneity can affect when and how a disease presents clinically in an individual with genetic predisposition to a condition and how individuals with a given disease will respond to specific treatments. Analyses of gene expression can be clinically useful for disease classification, diagnosis, prognosis, and tailoring treatment to underlying genetic determinants of pharmacologic response (e.g., breast cancer classification assays performed on tumor biopsy specimens) (Steiling and Christenson, 2023). However, there is a lack of evidence to support the use of gene expression classifiers and profiling (i.e., via whole blood specimen) for pharmacologic response.

### **U.S. Food and Drug Administration (FDA)**

The FDA considers the use of genomic information in drug labels either to require a genetic test for prescribing a drug, to recommend the use of a genetic test prior to drug therapy, or simply to provide information about the current knowledge of genomics that is relevant to drug therapy without the requirement or recommendation of a specific action. While the clinical utility of genotyping prior to treatment is not proven for all medications for which genomic information is included (Slavin, et al., 2015), clinical utility is established when identification of a specific gene biomarker is noted to be clinically necessary prior to initiating therapy with a specific drug target as noted within the FDA-approved prescribing label.

An FDA Safety Communication issued in 2018 warned against the use of many genetic tests with unapproved claims to predict patient response to specific medications. The Communication's intent was to alert patients and healthcare providers that for many genetic tests, claims to predict a patient's response to specific medications have not been reviewed by the FDA, and may not have the scientific or clinical evidence to support this use for most medications. Changing drug treatment based on the results from such a genetic test could lead to inappropriate treatment decisions and potentially serious health consequences for the patient. The FDA specifically noted the relationship between DNA variations and the effectiveness of antidepressant medication has never been established. According to the FDA, there are a limited number of cases for which at least some evidence does exist to support a correlation between a genetic variant and drug levels within the body, and this is described in the labeling of FDA-cleared or -approved genetic tests and FDA-approved medications.

### **Literature Review**

Increasingly, published, peer-reviewed scientific evidence regarding the clinical utility of pharmacogenetic testing informs on the ability of such testing to benefit health outcomes. Prospective clinical trials of standard management procedures compared with genetic test-directed management offers the highest level of evidence. Evidence may also be derived using banked samples from already-completed clinical trials, or by constructing an indirect chain of evidence linking test results to clinical outcome. To date, much of the existing research in the area of pharmacogenetic testing has been limited by study design, including uncontrolled and poorly defined case and control groups, presence of confounding variables, and the use of retrospective and non-blinded study protocols.

Although genome-wide association studies report inter-individual variability, high-quality, randomized controlled trial data demonstrating improved clinical outcomes are lacking. Many early phase clinical trials are exploratory, with no formal genomic hypothesis, and have small sample sizes that make it difficult to identify important gene variants influencing pharmacokinetics and pharmacodynamics (Lesko and Schmidt, 2014). However, clinical utility has been established for pharmacogenetic testing for a number of gene biomarkers and their specific drug targets.

Zeier et al. (2018) reviewed the evidence for several combinatorial pharmacogenetic test decision support tools whose potential utility to improve antidepressant treatment response or side effect burden has been evaluated in clinical settings. The authors noted available literature suffers from publication bias, because some products garner more investment than do others, and questions about scientific integrity are inherent in studies conducted by or reports authored by personnel with significant financial interests in the outcome. Although some of the preliminary published data sound promising, particularly with regard to the CYP450 gene variants and side effect burden, the authors concluded that there is insufficient evidence to support widespread use.

Wang et al. (2014) published results of a study evaluating the evidence that supports pharmacogenomic biomarker testing in drug labels and how frequently testing is recommended. Using guidelines published by the Evaluation of Genomic Applications in Practice and Prevention Working Group and FDA databases, the authors reviewed drug labels that described the use of a biomarker for reference to clinical validity and clinical utility. Of 119 notations in drug labels 36.1% provided evidence of clinical validity evidence while 15.1% provided evidence of clinical utility. Sixty-one labels (51.3%) made recommendations regarding clinical management based on the results of a biomarker test. Of these, 30.3% provided clinical utility data. A full description of supporting studies was included in 13 labels (10.9%). The authors noted that it may be premature to include biomarker recommendations in drug labels when data regarding patient outcomes are not available.

Pharmacogenetic testing is not currently recommended for general population screening. Clinical trials regarding the use of pharmacogenetic testing for screening in the general population are lacking in the published, peer-reviewed scientific literature and the role of such testing has not been established.

**Health Equity Considerations**

Health equity is the highest level of health for all people; health inequity is the avoidable difference in health status or distribution of health resources due to the social conditions in which people are born, grow, live, work, and age.

Social determinants of health are the conditions in the environment that affect a wide range of health, functioning, and quality of life outcomes and risks. Examples include safe housing, transportation, and neighborhoods; racism, discrimination and violence; education, job opportunities and income; access to nutritious foods and physical activity opportunities; access to clean air and water; and language and literacy skills.

**Medicare Coverage Determinations**

|     | Contractor                         | Determination Name/Number                            | Revision Effective Date |
|-----|------------------------------------|------------------------------------------------------|-------------------------|
| NCD | National                           | Pharmacogenomic Testing for Warfarin Response (90.1) | 8/3/2009                |
| LCD | Multiple LCDs                      | MolDX: Pharmacogenomics Testing                      | Varies                  |
| LCD | National Government Services, Inc. | Molecular Pathology Procedures (L35000)              | 8/1/2024                |
| LCD | Multiple LCDs                      | Pharmacogenomics Testing                             | Varies                  |

Note: Please review the current Medicare Policy for the most up-to-date information.  
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

**References**

1. American College of Medical Genetics and Genomics (ACMG). Medical Genetics Practice Resources. ©2024. Accessed Dec 13, 2024. Available at URL address: [https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Practice\\_Resources/ACMG/Medical-Genetics-Practice-Resources/Medical-Genetics-Practice-Resources.aspx](https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/Practice_Resources/ACMG/Medical-Genetics-Practice-Resources/Medical-Genetics-Practice-Resources.aspx)
2. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al.; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 Nov 27;116(22):2563-70.
3. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation. 2012 Apr 24;125(16):1997-2005. Epub 2012 Mar 19.
4. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundström S, Kaasa S, Dale O. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for

- cancer pain? A cross-sectional multicentre study. *Eur J Clin Pharmacol*. 2012 Jan;68(1):55-64.
5. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. *Clin Pharmacol Ther*. 2006 Apr;79(4):291-302.
  6. Association for Molecular Pathology (AMP). Practice Guidelines. ©2024. Accessed Dec 13, 2024. Available at URL address: <https://www.amp.org/clinical-practice/practice-guidelines/>
  7. Bae JW, Choi CI, Lee HI, Lee YJ, Jang CG, Lee SY. Effects of CYP2C9\*1/\*3 and \*1/\*13 on the pharmacokinetics of losartan and its active metabolite E-3174. *Int J Clin Pharmacol Ther*. 2012 Sep;50(9):683-9.
  8. Bakker PR, van Os J, van Harten PN. [The genetics of antipsychotic-related movement disorders]. *Tijdschr Psychiatr*. 2015;57(2):114-9.
  9. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. *BMJ*. 2011 Aug 4;343:d4588.
  10. Bhatt DL, Pare G, Eikelboom JW, Simonsen KL, Emison ES, Fox, KA, et al. The relationship between CYP2C10 polymorphisms and ischaemic and bleeding outcomes in stable patients: the CHARISMA genetics study. *Eur Heart J*. 2012 Sep;33(17):2143-50.
  11. Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. *J Psychiatr Res*. 2018 Jan;96:100-107.
  12. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Müller DJ, Richter MA. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. *Pharmacogenomics J*. 2013 Apr 2.
  13. Brown JT, Bishop JR. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. *Pharmacogenomics*. 2015 Aug 28.
  14. Byeon JY, Kim YH, Na HS, Jang JH, Kim SH, Lee YJ, Bae JW, Kim IS, Jang CG, Chung MW, Lee SY. Effects of the CYP2D6\*10 allele on the pharmacokinetics of atomoxetine and its metabolites. *Arch Pharm Res*. 2015 Aug 9.
  15. Cabaleiro T, Roman M, Ochoa D, Talegon M, Prieto-Perez R, Wojnicz A, Lopez-Rodriguez R, Novalbos J, Abad-Santos F. Evaluation of the relationship between sex, polymorphisms in cyp2c8 and cyp2c9 and pharmacokinetics of angiotensin receptor blockers. *Drug Metab Dispos*. 2013 Jan;41(1):224-9.
  16. Candiotti KA, Yang Z, Rodriguez Y, Crescimone A, Sanchez GC, Takacs P, Medina C, Zhang Y, Liu H, Gitlin MC. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption. *Pain Med*. 2009 Jul-Aug;10(5):799-805.

17. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. *Clin Pharmacol Ther.* 2008 Mar;83(3):460-70.
18. Centers for Disease Control and Prevention (CDC). Genomics and Precision Health. Assessing Pharmacogenetic Variation in the United States to Enhance Health Equity of Pharmacogenetic Testing. Mar 15, 2022. (Archived). Accessed Dec 16, 2024. Available at URL address: <https://blogs.cdc.gov/genomics/2022/03/15/assessing-pharmacogenetic/>
19. Centers for Medicare & Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed Dec 13, 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/local-coverage-final-lcds-alphabetical-report.aspx?lcdStatus=all>
20. Centers for Medicare & Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed Dec 13, 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/reports/national-coverage-ncd-report.aspx?chapter=all&sortBy=title>
21. Céspedes-Garro C, Jiménez-Arce G, Naranjo ME, Barrantes R, Llerena A; CEIBA. FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF. Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans. *Rev Biol Trop.* 2014 Dec;62(4):1659-71
22. Cicali EJ, Mosley SA, Cavallari LH. Pharmacogenetics. In: Wecker L, Ingram SL. Brody's Human Pharmacology. Philadelphia, PA: Elsevier; 2025. 41-48.
23. Claudio-Campos K, Duconge J, Cadilla CL, Ruano G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. *Drug Metabol Personal Ther.* 2015 Jun;30(2):87-105.
24. Clinical Pharmacogenetics Implementation Consortium (CPIC). Guidelines. Accessed Dec 13, 2024. Available at URL address: <https://cpicpgx.org/guidelines/>
25. College of American Pathologists (CAP). CAP Guidelines. Accessed Dec 16, 2024. Available at URL address: <https://www.cap.org/protocols-and-guidelines/cap-guidelines>
26. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. *Lancet.* 2009 Jan 24;373(9660):309-17.
27. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. *Blood.* 2008 Aug 15;112(4):1022-7.
28. Cresci S, Depta JP, Lenzini PA et al. Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction. *Circ Cardiovasc Genet.* 2014 Jun;7(3):277-86. Epub 2014 Apr 24.
29. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. *Clin Pharmacol Ther.* 2012;92(4):467-475.

30. Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, et al. Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non-responder patients after coronary stenting. *Arch Cardiovasc Dis*. 2010 Jan;101(1):39-45.
31. Daly AK, Cascorbi I. Opportunities and limitations: the value of pharmacogenetics in clinical practice. *Br J Clin Pharmacol*. 2014 Apr;77(4):583-6.
32. de Leon J, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. *J Clin Psychiatry*. 2005 Jan;66(1):15-27.
33. Dubovsky SL. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. *Expert Opin Drug Metab Toxicol*. 2015 Mar;11(3):369-79.
34. Ehmann F, Caneva L, Papluca M. European Medicines Agency initiatives and perspectives on pharmacogenomics. *Br J Clin Pharmacol*. 2014 Apr; 77(4): 612–617.
35. Epstein RS, Moyer TP, Aubert RE, O'Kane DJ, Xia F, Verbrugge RR, et al. Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study). *J Am Coll Cardiol*. 2010 Apr 7.
36. Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. *J Thromb Haemost*. 2010;8(1):95-100.
37. Ferreira PG, Costa S, Dias N, Ferreira AJ, Franco F. Simultaneous interstitial pneumonitis and cardiomyopathy induced by venlafaxine. *J Bras Pneumol*. 2014 May-Jun;40(3):313-8.
38. Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. *Pharmacogenet Genomics*. 2013 Aug;23(8):403-14.
39. Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. *J Thromb Haemost*. 2014 Sep;12(9):1480-7.
40. Franco V, Perucca E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. *Expert Opin Drug Metab Toxicol*. 2015 Aug; 11(8):1269-79.
41. Frere C, Cuisset T, Morange PE, Quicili J, Camion-Jau L, Suat N, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. *Am J Cardiol*. 2008 Apr 15;101(8):1088-93.
42. Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. *Thromb Res*. 2014 Sep;134(3):537-44.
43. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis of the PRINC (Plavix Response in Coronary Intervention) trial. *JACC Cardiovasc Interv*. 2008 Dec;1(6):620-7.

44. Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Provôt F, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation. *Nephrol Dial Transplant*. 2011 Sep;26(9):3046-50.
45. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. *J Clin Oncol*. 2005 Dec 20;23(36):9312-28.
46. Goetz MP, Sangkuhl K, Guchelaar H-J, et al. Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. *Clin Pharmacol Ther*. 2018.
47. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBaptista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. *J Psychiatr Res*. 2019;111:59-67.
48. Guilherme SK and Botton MR. Pharmacogenomics of warfarin in populations of African descent. *Br J Clin Pharmacol*. 2013 Feb;75(2):334-346.
49. Guisti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. *Am J Cardiol*. 2009 Mar 15;103(6):806-11.
50. Haas DW, Ribaud HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. *AIDS*. 2004 Dec 3;18(18):2391-400.
51. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, Drews MS, Eisterhold LL, Geske J, Mrazek DA. Utility of integrated pharmacogenomics testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. *Pharmacogenet Genomics*. 2013 Oct;23(10):535-48.
52. Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. *Clin Toxicol (Phila)*. 2015 Jul;53(6):501-10.
53. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. *Clin Med Res*. 2005 Aug;3(3):137-45.
54. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. *JAMA*. 2011 Dec 28;306(24):2704-14.
55. Horne BD, Lenzini PA, Wadelius M, Jorgensen AL, Kimmel SE, Ridker PM, et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. *Thromb Haemost*. 2012 Feb;107(2):232-40. Epub 2011 Dec 21.

56. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. *Pharmacogenet Genomics*. 2009 Mar;19(3):226-34.
57. Hulot JS, Cullot JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. *Circ Cardiovasc Interv*. 2011 Oct 1;4(5):422-8.
58. Hulot JS, Cullot JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19\*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. *J Am Coll Cardiol*. 2010 Jul 6;56(2):134-43.
59. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med*. 2009 Feb 19;360(8):753-64.
60. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update. *Clin Pharmacol Ther*. 2017;102(3): 397-404.
61. Jurgens G, Rasmussen HB, Werge T, Dalhoff K, Nordentoft M, Andersen SE. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum? *J Clin Psychopharmacol*. 2012 Feb;32(1):100-5.
62. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. *J Gen Intern Med*. 2009 May;24(5):656-64.
63. Kringen MK, Haug KB, Grimholt RM, Stormo C, Narum S, Opdal MS, et al. Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. *J Biomed Biotechnol*. 2011;2011:739-751.
64. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev*. 2002 Nov 18;54(10):1271-94.
65. Langley MR, Booker JK, Evans JP, McLeod HL, Weck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. *J Mol Diagn*. 2009 May;11(3):216-25.
66. Lassen D, Damkier P, Brøsen K. The Pharmacogenetics of Tramadol. *Clin Pharmacokinet*. 2015 Aug;54(8):825-36.
67. Lee JM, Park S, Shinn DJ, Choi D, Shim CY, Yo YG, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantations in Koreans. *Am J Cardiol*. 2009 Jul 1;104(1):46-51.
68. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgenson AL, Pirohamed M, et al. Integration of genetic, clinical and INR data to refine warfarin dosing. *Clin Pharmacol Ther*. 2010 May;87(5):572-8.

69. Lesko LJ, Schmidt S. Clinical implementation of genetic testing in medicine: a US regulatory science perspective. *Br J Clin Pharmacol*. 2014 Apr; 77(4): 606–611.
70. Li KX, Loshak H. Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; Jan 31, 2020. Accessed Dec 16, 2024. Available at URL address: <https://www.cadth.ca/pharmacogenomic-testing-depression-review-clinical-effectiveness-cost-effectiveness-and-guidelines>
71. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, et al. Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on Warfarin. *Clin Pharmacol Ther*. 2007 Jul 25.
72. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. *Clin Pharmacol Ther*. 2005 Nov;78(5):540-50.
73. Linares OA, Daly D, Linares AD, Stefanovski D, Boston RC. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. *Pain Med*. 2014 May;15(5):791-806.
74. Lorenzini K, Calmy A, Ambrosioni J, Assouline B, Daali Y, Fathi M, Rebsamen M, Desmeules J, Samer CF. Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. *AIDS*. 2012 Nov 28;26(18):2417-8.
75. Magavern EF, Gurdasani D, Ng FL, Lee SS. Health equality, race and pharmacogenomics. *Br J Clin Pharmacol*. 2022 Jan;88(1):27-33.
76. Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, Sahu A, Bass E, Kao WH, Clark JM. The pharmacogenetics of type 2 diabetes: a systematic review. *Diabetes Care*. 2014;37(3):876-86.
77. McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, et al. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. *Ther Drug Monit*. 2010 Jun;32(3):338-45.
78. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI—a meta-analysis. *JAMA*. 2010 Oct 27;304(16):1821-30.
79. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, Murphy SA, Lee J, Mercuri MF, Giugliano RP, Antman EM, Braunwald E, Sabatine MS. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. *Lancet*. 2015 Jun;385(9984):2280-7.
80. Mehta R, Kelleher D, Preece A, Hughes S, Crater G, et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. *Int J Chron Obstruct Pulmon Dis*. 2013;8:159-67. Epub 2013 Mar 27.
81. Monte AA, Heard KJ, Campbell J, Hamamura D, Weinshilboum RM, Vasiliou V. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness. *Acad Emerg Med*. 2014 Aug;21(8):879-85

82. Musunuru K, Hickey KT, Al-Khatib SM, et al. Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians: A Scientific Statement from the American Heart Association. *Circ Cardiovas Genet*. 2015;8:216-242.
83. Nakamura A, Mihara K, Nemoto K, Nagai G, Kagawa S, Suzuki T, Kondo T. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia. *Ther Drug Monit*. 2014 Dec;36(6):815-8.
84. National Center for Biotechnology Information (NCBI). U.S. National Library of Medicine. GTR: Genetic Testing Registry. Accessed Dec 16, 2024. Available at URL address: <https://www.ncbi.nlm.nih.gov/gtr/genes/>
85. National Institute for Health and Care Excellence (NICE). CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. DG59. Jul 31, 2024. Accessed Dec 16, 2024. Available at URL address: <https://www.nice.org.uk/guidance/dg59>
86. National Institute for Health Research (NIHR). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. *Health Technol Assess*. 2010 Jan;14(3):1-157, iii. Accessed Jan 8, 2024. Available at URL address: <https://www.journalslibrary.nihr.ac.uk/hta/hta14030/#/abstract>
87. National Institutes of Health (NIH). U.S. National Library of Medicine. MedlinePlus. Accessed Dec 16, 2024. Available at URL address: <https://medlineplus.gov/genetics/>
88. Ong FS, Deignan JL, Kuo JZ, Bernstein KE, Rotter JI, Grody WW, et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. *Pharmacogenomics*. 2012 Mar;13(4):465-75.
89. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. *J Clin Psychopharmacol*. 2013 Feb;33(1):3-10.
90. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. *Clin Pharmacol Ther*. 2014 Feb;95(2):216-27.
91. Prows CA, Zhang X, Huth MM, Zhang K, Saldaña SN, Daraiseh NM, Esslinger HR, Freeman E, Greinwald JH, Martin LJ, Sadhasivam S. Codeine-related adverse drug reactions in children following tonsillectomy: a prospective study. *Laryngoscope*. 2014 May;124(5):1242-50.
92. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. *N Engl J Med*. 2005 Jun 2;352(22):2285-93.
93. Rietveld L, van der Hoek T, van Beek MH, Schellekens AF. Familial liability for metoprolol-induced psychosis. *Gen Hosp Psychiatry*. 2015 Jun 25. pii: S0163-8343(15)00153-X

94. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGENet systematic review and meta-analysis. *Genet Med*. 2005 Feb;7(2):97-104.
95. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. *Br J Pharmacol*. 2010 Jun;160(4):919-30.
96. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. *Int Clin Psychopharmacol*. 2009 Sep;24(5):250-6.
97. Shah RR. Genotype-guided warfarin therapy: Still of only questionable value two decades on. *J Clin Pharm Ther*. 2020;45(3):547-560.
98. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome P450 2C19\*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. *Circulation*. 2010 Feb 2;121(4):512-8.
99. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, et al. Phenotyping vs genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. *J Thromb Haemost*. 2012 Apr;10(4):529-42.
100. Slavin TP, Niell-Swiler M, Solomon I, Nehoray B, Rybak C, Blazer KR, Weitzel JN. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. *Front Oncol*. 2015 Sep 29;5:208.
101. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome p450 2C19(\*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. *Pharmacogenomics J*. 2010 Mar 30.
102. Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. *J Neural Transm*. 2015 Jan;122(1):5-28.
103. Steiling K, Christenson S. Tools for genetics and genomics: Gene expression profiling. In: UpToDate, Tirnauer JS (Ed). Oct 2, 2023. UpToDate, Waltham, MA. Accessed Dec 16, 2024.
104. Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. *JAMA Intern Med*. 2014;174(8):1330-1338.
105. Sun F, Bruening W, Uhl S, Ballard R, Tipton K, Schoelles K. Quality, regulation and clinical utility of laboratory developed molecular tests. Technology assessment report. LABC0707. Original date May 19, 2010. Accessed Dec 16, 2024. Available at URL address: <https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id72TA.pdf>
106. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major

- depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. *PLoS Med.* 2012;9(10):e1001326.
107. Tayeh MK, Gaedigk A, Goetz MP, Klein TE, Lyon E, McMillin GA, Rentas S, Shinawi M, Pratt VM, Scott SA; ACMG Laboratory Quality Assurance Committee. Electronic address: documents@acmg.net. Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2022 Apr;24(4):759-768.
  108. Terasawa T, Dahabreh I, Castaldi PJ, et al. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jun 7.
  109. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. *Pharmacogenet Genomics.* 2012 Aug;22 (8):642-5.
  110. Thakur M, Grossman I, McCrory DC, Orlando LA, Steffens DC, Cline KE, et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. *Genet Med.* 2007 Dec;9(12):826-35.
  111. U.S. Department of Veterans Affairs; U.S. Department of Defense. VA/DoD Clinical practice guideline for the management of major depressive disorder. 2022. Accessed Dec 16, 2024. Available at URL address: <https://www.healthquality.va.gov/guidelines/MH/mdd/index.asp>
  112. U.S. Food and Drug Administration (FDA). Drugs@FDA: FDA-Approved Drugs. Accessed Dec 16, 2024. Available at URL address: <https://www.accessdata.fda.gov/scripts/cder/daf/>
  113. U.S. Food and Drug Administration (FDA). Guidance Document. Drug Metabolizing Enzyme Genotyping System - Class II Special Controls Guidance for Industry and FDA Staff document. Mar 10, 2005. Accessed Dec 16, 2024. Available at URL address: <https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/drug-metabolizing-enzyme-genotyping-system-class-ii-special-controls-guidance-industry-and-fda-staff>
  114. U.S. Food and Drug Administration (FDA). Guidance Document. Pharmacogenetic Tests and Genetic Tests for Heritable Markers. Guidance for Industry and FDA Staff. Jun 19, 2007. Accessed Dec 16, 2024. Available at URL address: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenetic-tests-and-genetic-tests-heritable-markers>
  115. U.S. Food and Drug Administration (FDA). Guidance Document. Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling. Jan 2013. Accessed Dec 16, 2024. Available at URL address: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacogenomics-premarket-evaluation-early-phase-clinical-studies-and-recommendations>

116. U.S. Food and Drug Administration (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling. Updated Sep 23, 2024. Accessed Dec 16, 2024. Available at URL address: <https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling>
117. U.S. Food and Drug Administration (FDA). 510(k) Premarket Notification. Drug metabolizing enzyme genotyping systems. Roche AmpliChip Cytochrome P450 P450 2C19-K043576. Jan 10, 2005. Accessed Dec 16, 2024. Available at URL address: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K043576>
118. Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. *Clin Pharmacokinet*. 2015 Jul 1.
119. Wang B, Canestaro WJ, Choudhry NK. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. *JAMA Intern Med*. 2014 Dec;174(12):1938-44.
120. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J*. 2011 Aug;11(4):274-86.
121. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. *Clin Pharmacol Ther*. 2021 Sep;110(3):563-572.
122. Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. *Discov Med*. 2013 Nov;16(89):219-27.
123. Xi B, Wang C, Liu L, Zeng T, Liang Y, Li J, Mi J. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. *Hypertens Res*. 2011 Nov;34(11):1216-20.
124. Zabalza M, Subirana I, Sala J, Lluís-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. *Heart*. 2012 Jan;98(2):100-8.
125. Zeier Z, Carpenter LL, Kalin NH, et al. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. *Am J Psychiatry*. 2018;175(9):873-886.
126. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. *Clin Pharmacol Ther*. 2009 Dec;86(6):609-18.
127. Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for *Helicobacter pylori* eradication: a meta-analysis. *Helicobacter*. 2008 Dec;13(6):532-41.

128. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48(11):689-723.
129. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804.
130. Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R Jr, Linder MW. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007 Jul;53(7):1199-205.
131. Zubenko GS, Sommer BR, Cohen BM. On the marketing and use of pharmacogenetics tests for psychiatric treatment. JAMA Psychiatry. 2018 Aug 1;75(8):769-770.

## Revision Details

| Type of Revision | Summary of Changes                                                                                                     | Date       |
|------------------|------------------------------------------------------------------------------------------------------------------------|------------|
| Focused Review   | <ul style="list-style-type: none"> <li>No clinical policy statement changes.</li> </ul>                                | 10/15/2025 |
| Annual Review    | <ul style="list-style-type: none"> <li>No clinical policy statement changes.</li> </ul>                                | 2/15/2025  |
| Focused Review   | <ul style="list-style-type: none"> <li>No clinical policy statement changes.</li> </ul>                                | 11/1/2024  |
| Annual Review    | <ul style="list-style-type: none"> <li>Revised policy statement for biomarker genotyping/mutation analysis.</li> </ul> | 2/15/2024  |

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.